Individual variability in cyclosporin A sensitivity

The assessment of functional measures on CD28-mediated costimulation of human whole blood T lymphocytes

Christoph Härtel, Hans Jörg Hammers, Peter Schlenke, Lutz Fricke, Nina Schumacher, Holger Kirchner, Michael Müller-Steinhardt

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The quantitative analysis of cyclosporin A (CsA) effects might be helpful for optimizing immunosuppressive treatment after allogeneic organ transplantation in individual patients, as rejection can occur despite the existence of CsA blood levels within therapeutic ranges. Previous investigations found that costimulation of the CD28 pathway generally mediates CsA-resistant proliferation of T cell receptor (TCR)-activated T lymphocytes. However, here we describe considerable interindividual variation regarding the immunosuppressive effects of CsA (1000 μg/L) on anti-CD3/CD28 T cell costimulation in a human whole blood assay. In the in vitro study, we found a significant reduction of T cell proliferation, activation marker expression (CD25, CD69) on the T cell surface, and interleukin-2 (IL-2) protein expression in whole blood samples of all healthy subjects (n = 11). However, the investigation of cytokine mRNA profiles revealed variable results of in vitro CsA sensitivity. Whole blood samples of 3 of 11 healthy individuals demonstrated a marked suppression of IL-2 mRNA expression (>50%) and a partial inhibition of IL-4, interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α) mRNA expression on addition of CsA. In contrast, the remaining 8 healthy individuals had cytokine mRNA expression levels that were unaffected or even increased when CsA was administered in vitro. In patients undergoing CsA monotherapy (ex vivo study, n = 9), we found a significant suppression of IL-2 mRNA levels in 4 of 9 patients ex vivo. Thus, we cannot confirm a universal CsA resistance of T cells on anti-CD3/CD28 costimulation. Instead, our results suggest an individual degree of CsA sensitivity that might be more consistent with clinical experience. Prospective studies are necessary to determine if individual degrees of CsA sensitivity correlate with clinical events and are associated with a low or high risk of transplant rejection.

Original languageEnglish (US)
Pages (from-to)91-99
Number of pages9
JournalJournal of Interferon and Cytokine Research
Volume23
Issue number2
DOIs
StatePublished - Feb 1 2003

Fingerprint

Cyclosporine
T-Lymphocytes
Messenger RNA
Interleukin-2
Immunosuppressive Agents
Cytokines
Homologous Transplantation
Graft Rejection
Organ Transplantation
T-Cell Antigen Receptor
Interleukin-4
Interferons
Healthy Volunteers
Tumor Necrosis Factor-alpha
Cell Proliferation
Prospective Studies
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Cell Biology

Cite this

Individual variability in cyclosporin A sensitivity : The assessment of functional measures on CD28-mediated costimulation of human whole blood T lymphocytes. / Härtel, Christoph; Hammers, Hans Jörg; Schlenke, Peter; Fricke, Lutz; Schumacher, Nina; Kirchner, Holger; Müller-Steinhardt, Michael.

In: Journal of Interferon and Cytokine Research, Vol. 23, No. 2, 01.02.2003, p. 91-99.

Research output: Contribution to journalArticle

Härtel, Christoph ; Hammers, Hans Jörg ; Schlenke, Peter ; Fricke, Lutz ; Schumacher, Nina ; Kirchner, Holger ; Müller-Steinhardt, Michael. / Individual variability in cyclosporin A sensitivity : The assessment of functional measures on CD28-mediated costimulation of human whole blood T lymphocytes. In: Journal of Interferon and Cytokine Research. 2003 ; Vol. 23, No. 2. pp. 91-99.
@article{be8111bf8e8d4d529be167e4042043e9,
title = "Individual variability in cyclosporin A sensitivity: The assessment of functional measures on CD28-mediated costimulation of human whole blood T lymphocytes",
abstract = "The quantitative analysis of cyclosporin A (CsA) effects might be helpful for optimizing immunosuppressive treatment after allogeneic organ transplantation in individual patients, as rejection can occur despite the existence of CsA blood levels within therapeutic ranges. Previous investigations found that costimulation of the CD28 pathway generally mediates CsA-resistant proliferation of T cell receptor (TCR)-activated T lymphocytes. However, here we describe considerable interindividual variation regarding the immunosuppressive effects of CsA (1000 μg/L) on anti-CD3/CD28 T cell costimulation in a human whole blood assay. In the in vitro study, we found a significant reduction of T cell proliferation, activation marker expression (CD25, CD69) on the T cell surface, and interleukin-2 (IL-2) protein expression in whole blood samples of all healthy subjects (n = 11). However, the investigation of cytokine mRNA profiles revealed variable results of in vitro CsA sensitivity. Whole blood samples of 3 of 11 healthy individuals demonstrated a marked suppression of IL-2 mRNA expression (>50{\%}) and a partial inhibition of IL-4, interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α) mRNA expression on addition of CsA. In contrast, the remaining 8 healthy individuals had cytokine mRNA expression levels that were unaffected or even increased when CsA was administered in vitro. In patients undergoing CsA monotherapy (ex vivo study, n = 9), we found a significant suppression of IL-2 mRNA levels in 4 of 9 patients ex vivo. Thus, we cannot confirm a universal CsA resistance of T cells on anti-CD3/CD28 costimulation. Instead, our results suggest an individual degree of CsA sensitivity that might be more consistent with clinical experience. Prospective studies are necessary to determine if individual degrees of CsA sensitivity correlate with clinical events and are associated with a low or high risk of transplant rejection.",
author = "Christoph H{\"a}rtel and Hammers, {Hans J{\"o}rg} and Peter Schlenke and Lutz Fricke and Nina Schumacher and Holger Kirchner and Michael M{\"u}ller-Steinhardt",
year = "2003",
month = "2",
day = "1",
doi = "10.1089/107999003321455480",
language = "English (US)",
volume = "23",
pages = "91--99",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Individual variability in cyclosporin A sensitivity

T2 - The assessment of functional measures on CD28-mediated costimulation of human whole blood T lymphocytes

AU - Härtel, Christoph

AU - Hammers, Hans Jörg

AU - Schlenke, Peter

AU - Fricke, Lutz

AU - Schumacher, Nina

AU - Kirchner, Holger

AU - Müller-Steinhardt, Michael

PY - 2003/2/1

Y1 - 2003/2/1

N2 - The quantitative analysis of cyclosporin A (CsA) effects might be helpful for optimizing immunosuppressive treatment after allogeneic organ transplantation in individual patients, as rejection can occur despite the existence of CsA blood levels within therapeutic ranges. Previous investigations found that costimulation of the CD28 pathway generally mediates CsA-resistant proliferation of T cell receptor (TCR)-activated T lymphocytes. However, here we describe considerable interindividual variation regarding the immunosuppressive effects of CsA (1000 μg/L) on anti-CD3/CD28 T cell costimulation in a human whole blood assay. In the in vitro study, we found a significant reduction of T cell proliferation, activation marker expression (CD25, CD69) on the T cell surface, and interleukin-2 (IL-2) protein expression in whole blood samples of all healthy subjects (n = 11). However, the investigation of cytokine mRNA profiles revealed variable results of in vitro CsA sensitivity. Whole blood samples of 3 of 11 healthy individuals demonstrated a marked suppression of IL-2 mRNA expression (>50%) and a partial inhibition of IL-4, interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α) mRNA expression on addition of CsA. In contrast, the remaining 8 healthy individuals had cytokine mRNA expression levels that were unaffected or even increased when CsA was administered in vitro. In patients undergoing CsA monotherapy (ex vivo study, n = 9), we found a significant suppression of IL-2 mRNA levels in 4 of 9 patients ex vivo. Thus, we cannot confirm a universal CsA resistance of T cells on anti-CD3/CD28 costimulation. Instead, our results suggest an individual degree of CsA sensitivity that might be more consistent with clinical experience. Prospective studies are necessary to determine if individual degrees of CsA sensitivity correlate with clinical events and are associated with a low or high risk of transplant rejection.

AB - The quantitative analysis of cyclosporin A (CsA) effects might be helpful for optimizing immunosuppressive treatment after allogeneic organ transplantation in individual patients, as rejection can occur despite the existence of CsA blood levels within therapeutic ranges. Previous investigations found that costimulation of the CD28 pathway generally mediates CsA-resistant proliferation of T cell receptor (TCR)-activated T lymphocytes. However, here we describe considerable interindividual variation regarding the immunosuppressive effects of CsA (1000 μg/L) on anti-CD3/CD28 T cell costimulation in a human whole blood assay. In the in vitro study, we found a significant reduction of T cell proliferation, activation marker expression (CD25, CD69) on the T cell surface, and interleukin-2 (IL-2) protein expression in whole blood samples of all healthy subjects (n = 11). However, the investigation of cytokine mRNA profiles revealed variable results of in vitro CsA sensitivity. Whole blood samples of 3 of 11 healthy individuals demonstrated a marked suppression of IL-2 mRNA expression (>50%) and a partial inhibition of IL-4, interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α) mRNA expression on addition of CsA. In contrast, the remaining 8 healthy individuals had cytokine mRNA expression levels that were unaffected or even increased when CsA was administered in vitro. In patients undergoing CsA monotherapy (ex vivo study, n = 9), we found a significant suppression of IL-2 mRNA levels in 4 of 9 patients ex vivo. Thus, we cannot confirm a universal CsA resistance of T cells on anti-CD3/CD28 costimulation. Instead, our results suggest an individual degree of CsA sensitivity that might be more consistent with clinical experience. Prospective studies are necessary to determine if individual degrees of CsA sensitivity correlate with clinical events and are associated with a low or high risk of transplant rejection.

UR - http://www.scopus.com/inward/record.url?scp=0345382796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345382796&partnerID=8YFLogxK

U2 - 10.1089/107999003321455480

DO - 10.1089/107999003321455480

M3 - Article

VL - 23

SP - 91

EP - 99

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 2

ER -